The research, conducted on Simmental bulls at an Egyptian livestock training centre, is the first to test this particular pairing in cryopreserved bull semen. Thyroxine, the thyroid hormone better known for regulating metabolism, has previously been shown to kick sperm into a state of hyperactive flagellar motion and to improve the recovery of morphologically normal cells. Melatonin, the pineal gland hormone that governs sleep cycles, is a potent antioxidant that scavenges free radicals and bolsters the cell’s own enzymatic defences. By shrinking melatonin down to nanoparticles roughly 22 nanometres across, the team aimed to squeeze far more protective power out of far smaller doses.

The experimental design was thorough. Over eight weeks, the researchers collected 96 ejaculates from six healthy, fertile Simmental bulls aged three to four years, twice weekly using an artificial vagina warmed to 40 to 42 degrees Celsius. Only samples meeting strict quality thresholds, at least 75 percent progressive motility, a volume of five millilitres or more, fewer than 10 percent abnormal sperm and a concentration of at least one billion sperm per millilitre, were accepted for freezing. Ejaculates from all six bulls were pooled on each collection day to smooth out individual variation, and each pool was treated as a single experimental replicate.

The melatonin nanoparticles themselves were synthesised from pharmaceutical-grade melatonin dissolved in double-distilled water, stirred, ultrasonicated, dried at 45 degrees Celsius and ground for ten hours into a fine homogeneous powder. X-ray diffraction confirmed the crystal structure, field-emission scanning electron microscopy revealed spherical particles with a non-smooth surface, and energy-dispersive X-ray analysis verified purity. The average grain diameter fell from 72 nanometres for bulk melatonin to 22 nanometres for the nano-formulation, and a zeta potential of minus 39.5 millivolts indicated good electrostatic stability in solution, a key factor in keeping nanoparticles from clumping together.

Semen was diluted into a standard Tris-egg yolk-glycerol extender and split into ten treatment groups: an untreated control, three thyroxine concentrations (0.5, 0.75 and 1.0 micrograms per decilitre), three nano-melatonin concentrations (30, 45 and 60 micrograms per decilitre) and three combination groups pairing the corresponding doses. The samples were cooled to 4 degrees Celsius over four hours, loaded into 0.25-millilitre straws and frozen in a programmable biofreezer, plunging at minus 30 degrees per minute down to minus 15 degrees and then minus 50 degrees per minute to minus 140 degrees, before storage in liquid nitrogen. Thawing took just 30 seconds in a 37-degree water bath.

When the thawed sperm were examined with a computer-assisted sperm analysis system tracking roughly 1,500 cells per sample at 60 frames per second, one combination stood out clearly. The pairing of 0.5 micrograms per decilitre thyroxine with 30 micrograms per decilitre nano-melatonin, dubbed T0.5 plus NM30, delivered the highest total motility at 58.31 percent and progressive motility at 52.38 percent, against 41.23 and 36.54 percent respectively in untreated controls. Sperm in this group also swam faster and straighter, posting top values for curvilinear velocity, straight-line velocity, straightness, linearity and beat cross frequency.

Functional tests told the same story. The winning combination produced the best viability at 60.69 percent, acrosome integrity at 75.69 percent, plasma membrane integrity measured by the hypo-osmotic swelling test at 57.23 percent, and mitochondrial membrane potential assessed with JC-10 flow cytometry at 58.77 percent. DNA integrity, evaluated with acridine orange staining, reached 92 percent, the highest of any group. Notably, higher thyroxine doses of 0.75 and 1.0 micrograms per decilitre performed worse than the lowest dose, echoing earlier reports that excessive thyroxine can inhibit cytochrome c oxidase and impair mitochondrial function.

The biochemical data revealed why the combination works. In the T0.5 plus NM30 group, glutathione peroxidase activity climbed to 21.31 nanomoles per minute per millilitre, superoxide dismutase reached 42.08 units per millilitre and total antioxidant capacity hit 2.25 millimolar, all significantly above controls, while malondialdehyde, the classic marker of lipid peroxidation, dropped to 0.61 micromoles per millilitre from 1.29 in controls. Annexin V and propidium iodide flow cytometry showed the combination also shifted cells away from death: viable non-apoptotic sperm rose to 63 percent, while late apoptotic and necrotic fractions fell to 18.46 and 8.39 percent respectively. The authors attribute this to complementary mechanisms, with thyroxine binding receptors outside the nucleus to trigger cyclic AMP and calcium release that fuels motility, and nano-melatonin neutralising reactive species, blocking the mitochondrial permeability transition pore and suppressing caspase-3 activation through pathways including SIRT-1/FOXO-1 and Nrf-2/HO-1.

The most striking result, however, came from the field. Because the lowest-dose combination had performed best in the laboratory, the team reserved it for a live fertility trial. One hundred and forty healthy cyclic cows were synchronised with a GPG hormone protocol and inseminated in August 2025 with frozen-thawed semen from four of the treatment groups, 35 cows each, with duplicate inseminations morning and evening. Pregnancy was confirmed by ultrasound on day 45. Cows receiving the combination semen achieved a conception rate of 82.86 percent, compared with 77.14 percent for nano-melatonin alone, 57.14 percent for thyroxine alone and just 48.57 percent for the control extender, a difference the authors describe as statistically significant.

The implications for the global artificial insemination industry could be considerable, since even modest gains in conception rates translate into substantial economic returns for dairy and beef producers. The nano-formulation is also appealing because it achieves strong effects at doses far below conventional melatonin supplements, which earlier studies have applied at up to 0.7 milligrams per millilitre. The authors caution that their study has limitations, including the use of pooled semen, the absence of molecular validation of the signalling pathways involved and relatively limited nanoparticle characterisation, and they call for future work to unpick the mechanisms underlying the synergy. Even so, the message is clear: a dash of thyroid hormone and a pinch of sleep-hormone nanoparticles may be exactly what frozen bull sperm needs to survive the deep freeze and deliver in the field.

Subject of Research: Effects of thyroxine and nano-melatonin supplementation on cryopreserved Simmental bull semen quality and fertility

Article Title: Synergistic Effects of Thyroxine and Nano‐Melatonin on Post‐Thaw Sperm Quality, Antioxidant Defence and Fertility of Cryopreserved Simmental Bull Semen

Article References: Abonagy, M., Arisha, A., Salama, M., Ashour, M., Shukry, M., Shedeed, S., Shehabeldin, A., El‐Shafai, N., Ibrahim, Z., Mahmoud, S., Saad, M., Alameen, A., Elkhidr, R. Y., Alif, O. H., Khalphallah, A., Elmeligy, E., Khesruf, K. A., Abdelhafez, E. A., & Algabary, A. (2026). Synergistic Effects of Thyroxine and Nano‐Melatonin on Post‐Thaw Sperm Quality, Antioxidant Defence and Fertility of Cryopreserved Simmental Bull Semen. Veterinary Medicine and Science, 12(6), Article e71252. https://doi.org/10.1002/vms3.71252

Image Credits: AI Generated

DOI: 10.1002/vms3.71252

Keywords: cryopreservation, bull semen, thyroxine, nano-melatonin, antioxidant defence, oxidative stress, sperm motility, mitochondrial membrane potential, apoptosis, artificial insemination, Simmental cattle, fertility

Ferroptosis is a form of regulated cell death that has captivated oncologists since its discovery. Unlike apoptosis, the tidy, programmed dismantling of a cell, ferroptosis is a violent, iron-driven process in which reactive oxygen species attack the fatty membranes that enclose cells. Lipid peroxidation spreads like a chemical wildfire until the membrane disintegrates. Under the microscope, cells dying by ferroptosis display shrunken mitochondria with increased membrane density and diminished cristae, the internal folds where respiration takes place. Because cancer cells run metabolically hot, accumulating oxidative stress as a byproduct of their rapid growth, they are often unusually vulnerable to this mode of death, making ferroptosis an attractive therapeutic lever.

The central antioxidant defense against ferroptosis is the glutathione peroxidase 4 enzyme, or GPX4, which detoxifies phospholipid hydroperoxides using glutathione as a cofactor. Starving cells of cysteine, the amino acid required to build glutathione, collapses this defense system. Cysteine depletion does more than drain glutathione: it also impairs the synthesis of coenzyme A, disrupting lipid metabolism, and destabilizes iron-sulfur clusters, which activates an iron-starvation response that increases iron uptake through the transferrin receptor. The result is an expanding pool of unliganded ferrous iron that fuels Fenton chemistry, generating a flood of reactive oxygen species and driving lethal lipid peroxidation. A compound called RSL3 can trigger the same endpoint more directly by binding to and inhibiting GPX4 outright.

Lapatinib, meanwhile, is an orally available small-molecule inhibitor that selectively blocks the tyrosine kinase activities of the epidermal growth factor receptor EGFR and its relative HER2, suppressing the downstream MAPK and PI3K/AKT survival pathways that tumors depend on. Previous studies had painted a confusing picture of its relationship with ferroptosis. In breast cancer cells, lapatinib promoted ferroptosis when combined with a lysosome-disrupting agent, accompanied by iron accumulation. More recently, it was reported to induce ferroptosis in osteosarcoma by disrupting glutamine uptake and glutathione synthesis. Yet in neuronal cells, lapatinib was found to suppress ferroptosis by restoring GPX4 expression. The new study set out to resolve how the drug behaves when ferroptosis is induced by cysteine deprivation in non-small cell lung cancer cells.

The research team, led by investigators at the Korea Institute of Radiological and Medical Sciences and collaborating institutions, worked with two human lung cancer cell lines, H1299 and H23. When the cells were deprived of cysteine for 24 hours, viability in H1299 cells collapsed to roughly 30 percent of control levels. Remarkably, adding lapatinib restored viability in a dose-dependent manner, climbing back to about 65 percent at a concentration of 10 micromolar. In H23 cells, where cysteine deprivation cut viability to about a quarter of normal, lapatinib again rescued the cells dose-dependently. Crucially, two other EGFR-targeting drugs, erlotinib and gefitinib, offered no such protection, indicating that the effect is not a generic property of this drug class.

To confirm that the cell death in question was truly ferroptosis, the researchers deployed a panel of benchmark compounds. Ferrostatin-1 and liproxstatin-1, both inhibitors of lipid peroxidation, and deferoxamine, an iron chelator, all significantly blunted the viability loss caused by cysteine deprivation, whereas z-VAD-fmk, an apoptosis blocker, had no effect. That pharmacological fingerprint pointed squarely at ferroptosis. The team then measured malondialdehyde, a major end product of lipid peroxidation, and used the C11-BODIPY fluorescent probe to visualize membrane oxidation directly. Cysteine deprivation drove both markers sharply upward, and lapatinib pulled them back down in both cell lines, confirming that the drug was suppressing the lipid peroxidation cascade at its core.

The mechanistic surprises deepened from there. Cysteine deprivation and lapatinib each independently raised intracellular reactive oxygen species and ferrous iron levels when given alone. Yet when lapatinib was combined with cysteine deprivation, it significantly reduced ROS generation even though intracellular ferrous iron remained elevated, comparable to levels seen with lapatinib alone. Even more counterintuitively, lapatinib further depleted glutathione and further reduced GPX4 protein expression under cysteine-deprived conditions, the opposite of what a ferroptosis-suppressing intervention would be expected to do through the canonical antioxidant pathway. The drug also protected cells from RSL3, the direct GPX4 inhibitor, while again lowering GPX4 expression further, demonstrating that its protective effect operates entirely independently of the glutathione-GPX4 axis.

The answer, the researchers found, lies in the mitochondria. Both cysteine deprivation and RSL3 treatment caused hyperpolarization of the mitochondrial membrane potential, detected by increased TMRE fluorescence, along with a marked rise in oxygen consumption, signatures of revved-up mitochondrial metabolism that have previously been linked to mitochondrial ROS generation and ferroptotic death. Lapatinib alone produced only modest increases in these parameters, but when co-administered with either ferroptotic stimulus, it significantly blunted both the membrane hyperpolarization and the surge in oxygen consumption. By restraining excessive mitochondrial metabolic activation, lapatinib appears to cut off the supply of mitochondrial ROS that sustains lipid peroxidation, rendering the accumulated ferrous iron insufficient to keep the ferroptotic fire burning.

Why would lapatinib calm mitochondrial respiration? The authors point to a tantalizing clue from a recent computational study predicting that lapatinib interacts with SLC1A5, a glutamine transporter. Glutaminolysis, the conversion of glutamine into alpha-ketoglutarate that feeds the tricarboxylic acid cycle, is indispensable for cysteine deprivation-induced ferroptosis, because it supplies the mitochondrial fuel that drives the respiratory surge. If lapatinib disrupts glutamine metabolism, reduced glutaminolysis would dampen mitochondrial activation and thereby limit ROS generation, a hypothesis consistent with the team’s observations. The precise molecular mechanism, however, remains to be worked out, and the researchers are careful to frame this as a hypothesis rather than a settled explanation.

The therapeutic implications cut in an uncomfortable direction. Ferroptosis induction is increasingly viewed as a way to overcome resistance to conventional agents such as cisplatin, docetaxel and sorafenib, and to amplify the effects of chemotherapy, radiotherapy and immunotherapy. If lapatinib suppresses ferroptosis that depends on mitochondrial metabolic activation, then combining it with such strategies could inadvertently blunt their efficacy and contribute to therapeutic resistance. The study also reinforces a broader lesson now echoing through the ferroptosis field: drug effects on this cell death pathway are exquisitely context-dependent, shaped by cell type, metabolic state and the specific trigger involved. A drug that kills by ferroptosis in one setting may protect against it in another, and clinicians designing rational combinations will need to account for that metabolic fine print.

Subject of Research: Context-dependent regulation of ferroptotic cell death by the EGFR/HER2 inhibitor lapatinib in non-small cell lung cancer cells

Article Title: Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function

Article References: Kim, G., Jang, S.-K., Kim, D.-G., Kim, H., Hong, J., Park, I.-C., & Jin, H.-O. (2026). Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function. Medical Oncology, 43(11), Article 294. https://doi.org/10.1007/s12032-026-03402-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03402-7

Keywords: lapatinib, ferroptosis, cysteine deprivation, mitochondria, GPX4, glutathione, lipid peroxidation, reactive oxygen species, non-small cell lung cancer, EGFR inhibitors, RSL3, mitochondrial membrane potential

The team, led by Dola Roy of the Zoological Survey of India with colleagues from the ICAR-Central Institute of Freshwater Aquaculture, Bhairab Ganguly College, Sundarban Hazi Desarat College, and the University of Calcutta, exposed adult zebrafish to 0.4 milligrams per liter of cadmium chloride for 21 days at two temperatures: 26 degrees Celsius, near the species’ optimum, and 34 degrees Celsius, a heat-shock condition. The concentration represented one-tenth of the dose lethal to half the animals within 96 hours at 26 degrees, making it a genuinely sub-lethal challenge. Water was renewed every 48 hours and cadmium levels verified by atomic absorption spectroscopy, with untreated control groups maintained at both temperatures.

The headline result came from whole-body and organ-level metal analysis. Whole-body cadmium reached 96.57 micrograms per gram wet weight in fish exposed at 34 degrees, significantly higher than the 74.24 micrograms per gram measured at 26 degrees and vastly above the near-zero levels in controls. Tissue mapping revealed a striking hierarchy of accumulation: liver first, followed by ovary, gills, muscle, brain, and alimentary canal. Hepatic cadmium in the hot cadmium group hit 32.49 micrograms per gram, roughly a 2.4-fold amplification over fish poisoned at the cooler temperature.

The liver’s dominance as a cadmium sink reflects its role as the body’s detoxification hub, but the ovary’s second-place finish carries a worrying implication. The authors point to vitellogenesis, the yolk-building phase of egg maturation, during which the ovary becomes rich in metal-binding proteins that sequester cadmium into developing oocytes, where it persists because reproductive tissue has limited capacity for detoxification. Gills, despite being the primary entry route for waterborne metal, retain less thanks to their ion-regulatory and excretory mechanisms. The pattern suggests that warming waters may create a reproductive risk pathway for contaminated fish populations alongside the better-recognized hepatic toxicity.

A microscopic examination of liver architecture told a similarly grim story. Control livers showed textbook structure: polyhedral hepatocytes with central nuclei and clear blood sinusoids. Heat alone caused only mild blood congestion and swelling. Cadmium at 26 degrees produced dark granule deposits, vacuole formation, cellular swelling, nuclear degeneration, and disorganized hepatic cords. But the combination of cadmium and heat produced the most severe lesions, including fat degeneration, lobular disruption, hypertrophy, and widened sinusoids. Semiquantitative scoring graded the combined-stress group as the most damaged of all four conditions.

Biochemical profiling deepened the picture of systemic collapse. Glucose soared in the hot cadmium group to 224.4 milligrams per deciliter, more than eight times the control value, likely reflecting stress-hormone-driven gluconeogenesis and glycogenolysis to fuel detoxification and repair. Meanwhile, total protein, cholesterol, and triglycerides dropped sharply, indicating enhanced proteolysis and lipid depletion. Bilirubin climbed while calcium fell, the latter consistent with cadmium’s known hijacking of calcium uptake channels in the gills. The combined-stress fish showed the most extreme perturbations, and correlation analysis tied the glucose rise to bilirubin elevation, a signature of hepatic dysfunction.

The oxidative stress data reveal the mechanism by which heat turns up the toxic dial. Reactive oxygen species, measured by flow cytometry of liver cells stained with a fluorescent probe, rose to their highest level in the 34-degree cadmium group, well above the cadmium-only group and far above controls. Lipid peroxidation, a marker of membrane damage, followed the same pattern. The antioxidant enzymes superoxide dismutase and catalase were upregulated, along with glutathione-related defenses, but at elevated temperature this compensatory surge lagged behind the accelerating oxidative burden. The defense system, in effect, was running flat out and still losing.

Metallothionein tells a subtler tale. These cysteine-rich proteins bind cadmium and are widely used as biomarkers of metal exposure. Concentrations rose in cadmium-exposed fish, peaking at 67.06 nanograms per milliliter in the hot cadmium group, and immunofluorescence showed intense labeling in hepatocyte cytoplasm and nuclei. Yet the authors argue that induction, however robust, proved insufficient to counterbalance the increased cadmium burden at high temperature, leaving more unbound metal free to damage cells, while thermal stress may itself compromise the proteins’ folding and binding efficiency.

Perhaps the most consequential findings concern cell death. Annexin V and propidium iodide staining, a flow cytometric method that distinguishes live, early-apoptotic, and late-apoptotic cells, confirmed significant apoptosis in all cadmium-exposed groups. Intriguingly, the 26-degree cadmium fish had more early apoptotic cells, while the 34-degree group showed the highest proportion of late apoptosis and secondary necrosis, suggesting that heat accelerates cells down the death pathway. A JC-1 assay of mitochondrial membrane potential confirmed the route: the percentage of depolarized cells, a hallmark of the intrinsic apoptosis pathway involving cytochrome c release and caspase activation, was highest in the hot cadmium group at 31.37 percent, versus 13.75 percent in controls. Heat alone also depolarized mitochondria, indicating that warming by itself nudges cells toward death.

The authors are careful to note that extrapolation from laboratory zebrafish to natural ecosystems must be made cautiously, and they recommend future work with fluctuating rather than static temperature regimes and with commercially important species. Even so, the study establishes temperature as a critical determinant of both cadmium toxicokinetics, how much metal enters and where it lodges, and toxicodynamics, what that metal does once inside. As heatwaves intensify across freshwater habitats already burdened by industrial runoff, the findings warn that ecological risk assessments calibrated at historical temperatures may substantially underestimate the threat, and that the true cost of a warming world includes making old poisons newly potent.

Subject of Research: Interaction of elevated temperature and cadmium toxicity in zebrafish

Article Title: Temperature amplifies cadmium toxicity through bioaccumulation dynamics and hepatic cellular responses in Danio rerio

Article References: Roy, D., Mohapatra, M., Pal, S., Mitra, A., Sundaray, J. K., & Homechaudhuri, S. (2025). Temperature amplifies cadmium toxicity through bioaccumulation dynamics and hepatic cellular responses in Danio rerio. Discover Toxicology, 2(1), Article 26. https://doi.org/10.1007/s44339-025-00043-9

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00043-9

Keywords: zebrafish, cadmium, temperature stress, bioaccumulation, hepatotoxicity, oxidative stress, metallothionein, apoptosis, mitochondrial membrane potential, ecotoxicology, climate change, heavy metal pollution

Cutaneous melanoma is the most lethal and aggressive cancer of the skin, arising from malignant transformation of melanocytes and marked by rapid proliferation, high metastatic potential, and notorious resistance to conventional therapies. The latest epidemiological estimates from the International Agency for Research on Cancer counted 331,722 new cases and 58,667 deaths worldwide in 2022, and even as targeted therapies and immunotherapies have transformed the landscape, low response rates and acquired resistance continue to frustrate effective management. That unmet need is precisely why the study’s authors turned their attention to two signaling systems increasingly recognized as vulnerabilities in tumors: purinergic signaling, the extracellular communication network built on adenosine triphosphate and its breakdown products, and the inflammatory axis involving interleukin-6 and the NLRP3 inflammasome.

Purinergic signaling, first proposed in 1972, operates through P1 and P2 receptors that respond to a ladder of molecules: ATP, adenosine diphosphate, adenosine monophosphate, and adenosine. Depending on which molecules dominate the extracellular space, the same pathway can drive cell proliferation or push a cell toward apoptosis. In the tumor microenvironment, the balance tilts dangerously. Extracellular adenosine, generated in abundance, acts as a potent immunosuppressant, blunting the anti-tumor immune response. The levels of these signaling molecules are controlled largely by ectonucleotidases, membrane-bound enzymes known as CD39 and CD73, along with adenosine deaminase, which breaks adenosine down into inosine. CD39 converts ATP into ADP and AMP; CD73 then hydrolyzes AMP into adenosine. Overexpression of CD73 has been documented in pancreatic adenocarcinoma, thyroid cancer, and melanoma itself, and both CD39 and CD73 have been flagged as next-generation checkpoint targets for cancer therapy.

Against that backdrop, calcitriol offered an intriguing candidate. Previous work had shown that 1-alpha,25-dihydroxyvitamin D3 induces apoptosis in melanoma cells, enhances the anticancer effects of classical chemotherapy, inhibits proliferation and migration in breast cancer models, and can modulate IL-6 expression. Yet its mechanism of action on the purinergic system in melanoma had never been systematically explored. The research team hypothesized that calcitriol exerts a potent antineoplastic effect on cutaneous melanoma by modulating the activity and expression of ectonucleotidases, thereby rewiring the extracellular nucleotide landscape in favor of tumor cell death.

To test the hypothesis, the investigators cultured two human cutaneous melanoma cell lines, A375 and SK-MEL-28, treating them with calcitriol at 1, 10, and 50 nanomolar concentrations for 24 hours. The A375 line, which displays epithelial morphology and an invasive, metastatic profile, and SK-MEL-28, a polygonal melanoma line, were subjected to a battery of assays: MTT and fluorescence microscopy viability tests, measurements of mitochondrial transmembrane potential using the TMRE dye, detection of apoptotic bodies by acridine orange staining, wound-healing migration assays, and enzymatic quantification of ATP, ADP, and AMP hydrolysis alongside adenosine deaminase activity. Gene expression of CD39, CD73, IL-6, and NLRP3 was assessed by RT-qPCR, normalized to the housekeeping gene GAPDH and analyzed with the comparative delta-delta-CT method, with one-way ANOVA and Dunnett’s post hoc test applied throughout.

The results were striking and, in one respect, unexpectedly selective. In A375 cells, calcitriol significantly reduced viability at every concentration tested, with the MTT assay yielding P values of 0.0004 at 1 nM and below 0.0001 at 10 and 50 nM. Fluorescence microscopy independently corroborated the viability loss across all doses. Crucially, the treatment also collapsed the mitochondrial transmembrane potential of A375 cells at all concentrations, with statistical significance reaching P < 0.0001, a disruption consistent with the initiation of intrinsic apoptosis. Matching that mitochondrial signature, the treated cells showed marked nuclear fragmentation: apoptotic bodies rose significantly at all three doses, while cell counts fell in a dose-dependent manner. Wound-healing assays added another dimension, revealing that calcitriol inhibited A375 migration and wound closure at every concentration tested within just 24 hours, with P < 0.0001, a finding with obvious implications for blocking metastasis.

The SK-MEL-28 line told a different story. Calcitriol produced no significant reduction in its viability and left its mitochondrial potential untouched; at 1 nM, viability even increased slightly. The researchers point to a well-documented explanation: SK-MEL-28 cells express functionally lower levels of the vitamin D receptor than several other melanoma lines, rendering them resistant to calcitriol’s antiproliferative effects at nanomolar concentrations, with prior studies noting sensitivity only at much higher doses. The contrast between the two cell lines underscores that calcitriol’s anticancer activity depends on functional vitamin D receptor signaling, a caveat that will shape which patients might ultimately benefit from a calcitriol-based adjuvant strategy.

The deepest technical insight, however, came from the purinergic analysis. Calcitriol left ATP hydrolysis unchanged but significantly decreased ADP hydrolysis at 1 and 10 nM, with a modest increase at 50 nM, and reduced AMP hydrolysis at 10 and 50 nM. Because CD39 and CD73 jointly convert ATP down the cascade to adenosine, dampened AMP breakdown means less substrate for adenosine production. Consistent with that logic, adenosine deaminase activity, which depends on adenosine availability, dropped sharply at 10 and 50 nM. At the gene level, calcitriol downregulated CD39 expression at 10 and 50 nM and exerted a strong suppressive effect on CD73 at those same concentrations, P < 0.0001. Together, these changes describe a coherent suppression of the AMP-to-adenosine axis, the very pathway tumors exploit to generate immunosuppressive adenosine in their microenvironment. By throttling adenosine generation, calcitriol may indirectly loosen the tumor’s grip on local immunity.

The inflammatory arm of the study completed the picture. Extracellular nucleotide signaling is intimately connected to inflammation, and both IL-6 and NLRP3 have dual, sometimes controversial roles in cancer, with evidence linking them to tumor progression, chemoresistance, immune cell infiltration, and poor prognosis in melanoma. Calcitriol significantly downregulated IL-6 expression at 10 nM and 50 nM, and produced an equally robust reduction in NLRP3 gene expression, with P < 0.0001 at both doses. Given that IL-6 targeting has been proposed to abrogate melanoma growth and progression, and that NLRP3 is increasingly viewed as a therapeutic target capable of reducing chemoresistance, these transcriptional effects suggest calcitriol acts on multiple fronts at once: killing tumor cells directly, impairing their migratory capacity, starving the immunosuppressive adenosine pathway, and calming the pro-tumoral inflammatory circuitry.

The authors are careful about scope. Their analysis covered gene expression rather than protein levels, and only two cell lines were examined, which they acknowledge as a limitation given the distinct metabolic profiles of A375 and SK-MEL-28. They also stress that while the nanomolar concentrations used appear practical for in vivo applications, safety testing is required, and future animal studies should monitor calcium levels to guard against hypercalcemia, the classic toxicity of active vitamin D compounds. Encouragingly, the adjuvant concept already has clinical footprints: calcitriol has been shown to enhance the effects of cisplatin and dacarbazine in melanoma cells, to combine favorably with the VEGFR inhibitor Cediranib, and, in a prospective phase Ib study, to be well tolerated in metastatic melanoma patients receiving high-dose encapsulated calcitriol alongside temozolomide, with no significant secondary side effects reported. Combined with prior evidence that calcitriol can sensitize melanoma cells to proton beam irradiation, the new purinergic mechanism adds a mechanistic rationale to an accumulating clinical case. If subsequent in vivo work confirms that calcitriol’s ectonucleotidase modulation translates into restored anti-tumor immunity, the sunshine vitamin’s most potent form could find itself written into the melanoma treatment algorithm.

Subject of Research: Antineoplastic effects of calcitriol on cutaneous melanoma cells via purinergic signaling modulation

Article Title: Calcitriol, the active form of vitamin D, induces cell death and purinergic signaling modulation in cutaneous melanoma cells

Article References: da Silva, G. B., Narzetti, R. A., Dallagnol, P., Ozelame, B. C., Manica, D., Ramos, V. H. M., Kempka, A. P., & Bagatini, M. D. (2026). Calcitriol, the active form of vitamin D, induces cell death and purinergic signaling modulation in cutaneous melanoma cells. Medical Oncology, 43(10), Article 288. https://doi.org/10.1007/s12032-026-03412-5

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03412-5

Keywords: calcitriol, vitamin D, cutaneous melanoma, purinergic signaling, ectonucleotidases, CD39, CD73, apoptosis, mitochondrial membrane potential, IL-6, NLRP3, adjuvant therapy

The researchers built their investigation around one of the most widely used models of cellular inflammation. They treated RAW264.7 macrophages, a mouse immune cell line, with lipopolysaccharide, or LPS, a molecule derived from the outer membrane of certain bacteria that reliably provokes a fierce inflammatory response. LPS exposure mimics the molecular alarm bells that ring during infection and tissue injury, and it is a standard tool for probing how immune cells behave when the body’s danger signals are blazing. Within this model, the team set out to dissect what happens when the balance between two key proteins, SIRT1 and FOXO1, is disturbed.

SIRT1 is a deacetylase enzyme, a member of the sirtuin family that has long been associated with cellular longevity, metabolic regulation and stress resistance. It works chemically by removing acetyl groups from target proteins, altering their activity. FOXO1, meanwhile, is a transcription factor, a DNA-binding protein that switches genes on and off. Previous work had hinted that SIRT1 could modify FOXO1 and influence its function, but the downstream consequences for mitochondrial quality control and immune cell metabolism remained incompletely understood. The new study set out to test whether SIRT1 restrains FOXO1 and, in doing so, protects cells from runaway inflammation.

To manipulate the pathway, the researchers used molecular tools to silence SIRT1 or to force cells to overexpress FOXO1. Both interventions produced strikingly similar effects, revealing that SIRT1 normally acts upstream to hold FOXO1 in check. When SIRT1 was knocked down, or when FOXO1 was artificially elevated, the cells dramatically increased production of PINK1 and Parkin, the two central proteins of the mitophagy machinery. Mitophagy is the process by which cells identify damaged mitochondria and tag them for destruction and recycling, and PINK1 and Parkin are the quality-control officers who flag defective organelles for removal. In principle, mitophagy is beneficial, clearing out dysfunctional power plants before they leak harmful reactive molecules. But the study showed that too much of a good thing can be toxic.

With PINK1 and Parkin ramped up excessively, the macrophages suffered a collapse of mitochondrial membrane potential, the electrical gradient across the inner mitochondrial membrane that drives energy production. Using the JC-1 fluorescent probe, the team visualized this dissipation directly, finding that the cells’ cellular power stations were losing their charge. The consequences rippled outward. The cells released elevated amounts of tumor necrosis factor-alpha and interleukin-1 beta, two potent inflammatory cytokines that amplify immune responses and can damage surrounding tissue. Levels of malondialdehyde, a widely used marker of oxidative lipid damage, also climbed, indicating that the cells were under heavy oxidative stress. In short, the SIRT1-FOXO1 imbalance pushed the macrophages into a hyperinflammatory state.

The metabolic rewiring was equally dramatic. The team measured glucose uptake, lactate production and ATP levels, and all three rose when the axis was disrupted. Key glycolysis-related proteins were upregulated, pointing to a shift toward aerobic glycolysis, the glucose-burning mode famously favored by rapidly dividing and highly activated immune cells. This metabolic switch, sometimes called the Warburg-like state, allows activated macrophages to generate building blocks and rapid bursts of energy even when oxygen is plentiful. But it came at a cost: the cellular microenvironment became acidified, as the surplus glucose was converted into lactate and exported from the cells. The combination of cytokine flooding, oxidative damage and acidic surroundings paints a picture of a tissue environment primed for injury.

To confirm that these changes were driven by the autophagy machinery itself, the researchers deployed two pharmacological modulators acting at different points in the autophagy pathway. Rapamycin, an inhibitor of the mTOR pathway and a well-established enhancer of autophagy, further intensified the phenotypes triggered by the SIRT1-FOXO1 imbalance, worsening membrane potential loss and inflammatory output. Conversely, 3-methyladenine, known as 3-MA, which blocks an early step of autophagosome formation, attenuated the same phenotypes. This push-pull experiment provides mechanistic weight to the central claim: the inflammatory and metabolic damage observed when SIRT1 is silenced or FOXO1 is elevated flows substantially through excessive activation of mitophagy and the associated metabolic shift.

The broader significance of the work lies in its implications for the brain. Macrophage-like immune cells, including the brain’s resident microglia and infiltrating macrophages, are central players in neuroinflammation, the chronic or excessive inflammatory response within nervous tissue that accompanies ischemic stroke, traumatic brain injury and neurodegenerative disease. If the SIRT1-FOXO1 axis functions similarly in these cells, then bolstering SIRT1 activity or damping FOXO1 signaling could help keep mitochondrial quality control within healthy bounds, preserving energy metabolism and reducing the release of cytokines that injure vulnerable neurons. The authors propose that this pathway may represent a potential therapeutic target for neuroinflammatory diseases such as ischemic stroke, where limiting secondary inflammatory damage is a major unmet clinical need.

The study, conducted by researchers affiliated with the Second Affiliated Hospital of Xi’an Jiaotong University and the Affiliated Hospital of Yan’an University, was supported by the Yan’an Science and Technology Plan and the Shaanxi Provincial Health and Wellness Research Innovation Platform. As with all cell-line work, important caveats remain. RAW264.7 macrophages are a laboratory model, and the behavior of these engineered cells must be validated in primary cells, in animal models of stroke and eventually in human tissue before any clinical translation can occur. The doses of LPS and the genetic manipulations used in vitro do not perfectly reproduce the complex inflammatory milieu of a diseased brain. Nevertheless, the study offers a clear and testable model: SIRT1 negatively regulates FOXO1, and this restraint prevents excessive mitophagy, preserves mitochondrial membrane potential, restrains the glycolytic shift and keeps inflammatory cytokine release in check. For a field searching for ways to quiet the immune storm that follows brain injury, that model is a compelling roadmap for the next generation of experiments.

Subject of Research: The SIRT1-FOXO1 signaling axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages with implications for neuroinflammation.

Article Title: SIRT1/FOXO1 axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages: implications for neuroinflammation

Article References: Yang, X., Ai, X., Sun, H., & Shi, W. (2026). SIRT1/FOXO1 axis regulates mitophagy and glycolytic metabolism in LPS-stimulated macrophages: implications for neuroinflammation. BMC Neuroscience. https://doi.org/10.1186/s12868-026-01038-x

Image Credits: AI Generated

DOI: 10.1186/s12868-026-01038-x

Keywords: SIRT1, FOXO1, mitophagy, macrophages, glycolysis, neuroinflammation, LPS, inflammatory cytokines, ischemic stroke, mitochondrial membrane potential, PINK1, Parkin